A
Actio Biosciences
Genetics-driven small-molecule therapies for rare and common diseases using precision medicine
About Actio Biosciences
Actio Biosciences is a biotechnology startup that focuses on the development of new drugs for rare diseases. The company operates in the pharmaceutical industry, specifically in the niche of rare disease drug development. Their business model is based on the understanding that studying and developing treatments for rare diseases can lead to innovative treatment approaches for more common diseases.
The company's primary clients are healthcare providers and patients suffering from rare diseases. They also collaborate with joint marketing partners and other third parties, which could include other pharmaceutical companies, research institutions, and healthcare organizations.
Actio Biosciences makes money by developing and selling their proprietary drugs. They own the trademarks to their product names, which suggests that they have a portfolio of unique drugs. The company also seems to be open to partnerships and joint ventures, which could provide additional revenue streams.
It's important to note that the company emphasizes transparency and patient education. They make an effort to clearly explain what information they collect from patients and how they use it. They also encourage patients to discuss treatment options with their healthcare providers, indicating a patient-centric approach to their business.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Diego, United States
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 38.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2025 | $66M | $264M | Droia Oncology Ventures · Regeneron Ventures · Canaan · Euclidean Capital | ↗ |
| SERIES AOther financing | Sep 2023 | $55M | $220M | Canaan · Euclidean Capital · Droia Oncology Ventures · EcoR1 Capital | ↗ |
Growth signals
Latest recorded traffic for Actio Biosciences is 4K monthly website visits, up 53.8% over the last three months. Actio Biosciences's team grew 2.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Canaan- ECEuclidean Capital
Droia Oncology Ventures
EcoR1 Capital
Deerfield
Regeneron Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Actio Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Actio Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.